Mr. Ellis serves as the Chairman of the Board for January Therapeutics as well as the interim Chief Executive Officer. Mr. Ellis is an entrepreneur, business leader, investor, biochemist and molecular biologist who has worked in the biotechnology industry for over 20 years.

He has successfully grown multiple businesses including Thomson Instrument Company and is listed as inventor on more than 35+ patents. In his career Sam has successfully closed more than 100 deals in biotechnology-focused partnerships with large pharma, small pharma, academic, and government entities. He has collaborated to publish together with Genentech, Pfizer, Takeda, and other companies in ground breaking scientific areas. Sam is a regular speaker at PEP Talk & PEGS, speaking publicly at multiple conferences, and regularly gives technical seminars at companies around the world. 

In addition to his executive role at Thomson, Mr. Ellis is actively involved in life science investment firms, including Life Science Angels and Tech Coast Angels. Mr. Ellis educational background is in biochemistry and molecular biology, in which he received his B.S. from the University of California, San Diego. Mr. Ellis is also an inventor holding over 40 patents. 


Dr. Jackman is the Chief Operating Officer and Chief Financial Officer as well as a Co-Founder of January Therapeutics.   He has over 20 years of experience at the intersection of medicine, science, and business.  Previously, he led the venture-backed orphan drug startup Zacharon Pharmaceuticals from discovery stage through large pharma partnerships and an eventual sale to BioMarin.  

Prior to that, he headed the oncology business division at Vical, advancing 2 immuno-oncology biologics through a Phase 1 clinical trial and a Phase 3, worldwide 125-site clinical trial respectively. Robin also led a biopharma company in critical care medicine  from concept-stage through full CMC development, IND filings and into Phase 2 clinical efficacy trials. 

Dr. Jackman is expert at building and advancing new programs and platforms; drug discovery to clinical development and partnerships. In his career he has completed over $10 billion in deal value through 80+ partnerships, financings, and company sales.  Robin holds graduate degrees from Harvard Medical School and Harvard University, and an undergraduate degree from Stanford University.


Dr. Raheja is a Co-Founder of January Therapeutics and also serves as the company's Chief Scientific Officer.  He has 20 years of medicinal chemistry and drug discovery experience; having worked previously for Celgene, Pfizer, and Ontogen Therapeutics.  

Dr. Raheja has worked in multiple therapeutic areas including oncology, inflammation, neuroscience, dermatology, and antivirals.  He has delivered 10 development candidates as a project leader or from within his organizations, with multiple compounds reaching Phase 2 clinical trials.  Dr. Raheja is an inventor on 4 compounds currently in clinical trials or in late stage development in oncology and inflammatory disease.  

He previously founded Integrated Pharma Solutions, an independent drug discovery company. Dr. Raheja completed his post-doctoral training at University of Pennsylvania under the direction of the late Ralph Hirschmann and Amos B. Smith III, and his Ph.D. at Wayne State University.


Don Rindell has more than 30 years of senior executive experience in the life sciences industry.  He has held executive roles in global corporate development, business development, and device/technology strategy for several US and European pharmaceutical and medical device companies. 

Mr. Rindell is currently Managing Director of Camino International, LLC, a consulting practice for Business and Product Development. He recently managed the partnered pharmaco-diagnostic programs for Bristol Myers Squibb’s Translational Medicine initiatives for oncology and fibrosis.  Previously he served as Senior Director of Corporate Development at Amylin Pharmaceuticals, which was purchased by Bristol Myers Squibb.  At Amylin, he led a number of key global transactions with companies including Shionogi Pharmaceuticals, Biocon, Takeda Pharmaceuticals and selected device delivery companies.   He also provided management leadership to the Amylin Drug Delivery Team. He has previously held senior executive positions at CardioNet, Advanced Tissues Sciences, Braun/Thermoscan, Hybritech, and Syntex. 

Mr. Rindell received his B.A. degree in Economics from the College of Wooster and an M.B.A. from Pepperdine University Graduate School of Business.